Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Biological Therapy for Inflammatory Bowel Disease in Children

  • Na, So-Young (Department of Pediatrics, Dongguk University College of Medicine) ;
  • Shim, Jung-Ok (Department of Pediatrics, Korea University Medical Center)
  • Received : 2012.03.07
  • Accepted : 2012.03.14
  • Published : 2012.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

The pathogenesis of inflammatory bowel diseases is not very well understood; it is currently thought to be caused by the interaction between genetic factors, environmental factors, intestinal microbes, and immune factors. Biological agents such as anti-tumor necrosis factor (anti-TNF) are widely being used as therapeutic agents. Infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, has been demonstrated to have an effect in the induction and maintenance of remission in Crohn's disease in children. The effects of biological agents, typified by anti-TNFs, in inflammatory bowel disease in children; the recent concern on the administration of biological agents in combination with immunomodulators; and 'Top-down' therapy are some of the topics covered in this review.

Keywords

References

  1. Seo JK. Pediatric inflammatory bowel disease: Phenotype, genetic and therapeutic differences between early-onset and adult onset IBD. Korean J Pediatr Gastroenterol Nutr 2011;14:1-25.
  2. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel disease. Gastroenterology 2009;136:1182-97.
  3. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn disease. Gut 1994;35:360-2.
  4. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn disease. Gastroenterology 1999;117:527-35.
  5. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
  6. Hyams JS, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate to severe Crohn's disease in children. Gastroenterology 2007;132:863-73.
  7. Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR, et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin Gastroenterol Hepatol 2008;6:1378-84.
  8. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn disease. N Eng J Med 2010;1362:1383-95.
  9. Van Moerkercke W, Ackaert C, Jurgens M, Kasran A, Compernolle G, Ballet V, et al. Anti-TNF$\alpha$ Induced Severe Arthralgia as a Manifestation of Autoimmunity? Gastroenterology 2010;138(1 Suppl):60S-1S.
  10. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607.
  11. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
  12. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-60.
  13. Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Stephens M, Evans J, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol 2010;105:1430-6.
  14. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-36.
  15. Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36-41.
  16. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn disease: a metaanalysis. Clin Gastroenterol Hepatol 2009;7:874-81.
  17. Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastro Hepatol 2010;8:655-9.
  18. D'Haens G, Baert F, Van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn disease: an open randomised trial. Lanset 2008;371:660-7.
  19. Romeo E. Viola F, De Angelis G, Vernuccio A, Pannone V, Bizzarri B, et al. Infliximab As a First Choice Therapy in Children with Newly Diagnosed Crohn's Disease (CD) Promotes Long-Term Sustained Remission and Alters the Course of the Disease. Gastroenterology 2006;130(2 Suppl):S11.
  20. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, et al. Withdrawal of immunosuppression in Crohn disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008;134:1861-8.
  21. Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn disease treated with combination therapy. Am J Gastroenterol 2010;105:1142-9.

Cited by

  1. Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up vol.15, pp.4, 2012, https://doi.org/10.5223/pghn.2012.15.4.243
  2. Surgery in Pediatric Crohn's Disease: Indications, Timing and Post-Operative Management vol.20, pp.1, 2012, https://doi.org/10.5223/pghn.2017.20.1.14